Peptides DB
Research-centric peptide and protocol reference hub
Study 31 of 33Tirzepatide literatureEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · ObservationalHigh-impact journal2026

Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.

In a real-world setting, Tirzepatide was associated with a higher likelihood of treatment simplification compared to conventional GLP-1 receptor agonists.

Read at Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
4
Preclinical
21
Observational · this one
1
Open-label
4
Randomised
3
Reviews

Summary and findings

This study measured the effects of Tirzepatide (TZP) compared to conventional glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on treatment simplification in patients with type 2 diabetes mellitus over 12 months. The primary outcome was treatment simplification, defined as a reduction in the number of antidiabetic medications or insulin injections. TZP was associated with a higher likelihood of treatment simplification than GLP-1 RAs.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < .001.2026

Abstract

The authors’ words, as Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists supplied them

<h4>Objective</h4>Polypharmacy and complex insulin regimens increase the treatment burden of type 2 diabetes mellitus, highlighting the need for treatment simplification. Tirzepatide (TZP) is a novel antidiabetic agent that has demonstrated potent glucose-lowering and weight-reducing effects, possibly reducing the use of concomitant antidiabetic medications and insulin dose requirements. However, data regarding its effects on treatment simplification in real-world settings are limited.<h4>Methods</h4>This retrospective real-world study compared TZP with conventional glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for 12 months. The primary outcome measure was treatment simplification, defined as a reduction in the number of antidiabetic medications, insulin injections, or ≥50% reduction in total daily insulin dose. Propensity score overlap weighting and multiple imputations were performed.<h4>Results</h4>A total of 318 patients (TZP, n = 153; GLP-1 RAs, n = 165) were included. TZP was associated with a higher likelihood of treatment simplification than GLP-1 RAs (55% vs 25%; odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < .001), corresponding to an absolute risk difference of 30%. TZP also achieved greater reductions in hemoglobin A1C and body weight. These findings were consistent across sensitivity analyses.<h4>Conclusion</h4>In a real-world clinical setting, TZP was associated with higher rates of treatment simplification while improving metabolic outcomes.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Tirzepatide corpus

BCardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.American heart journal plus : cardiology research and practice · 2026 · n=11330 · 19.5% 5-point MACE for semaglutide vs 17.1% for tirzepatide, HR 1.03, 95% CI 0.94-1.12.HumanAIxekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026 · 31.7% IXE + TZP vs 0.8% IXE alone at 36 weeks, P<0.001.HumanCEnsemble-Based Segmental Helical Organization in an Aib-Rich Lipidated Peptide: Biomacromolecular Insights from High-Field NMR.Biomacromolecules · 2026 · Not reported in abstract.In vitroB12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obesity pillars · 2026 · n=249 · Mean weight loss was 19.9 ± 8.6% at 12 months.HumanBReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nature medicine · 2026 · Mean weight reduction was 16.1 kg (95% CI 15.9 to 16.2; P < 0.001).HumanAEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obesity pillars · 2026 · Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.Human